Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review
Bimmer E Claessen1,2, Paul Guedeney1,3, C Michael Gibson4
1The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NY.
Insights
Optimizing lipid management after acute coronary syndrome (ACS) is crucial for secondary prevention. Many patients undertreated for low-density lipoprotein cholesterol require intensified therapy to reduce cardiovascular events and mortality.
Area of Science:
- Cardiology
- Preventive Medicine
- Pharmacology
Background:
- Acute coronary syndrome (ACS) is a leading cause of death despite advances in care.
- Suboptimal lipid management leads to undertreatment and failure to reach guideline-recommended low-density lipoprotein cholesterol (LDL-C) levels.
- A significant percentage of ACS survivors experience recurrent ischemic events and mortality within five years.
Purpose of the Study:
- To review current evidence on lipid management post-ACS.
- To identify patients benefiting from early intensified lipid-lowering therapy.
- To discuss emerging lipid-lowering medications and propose a treatment algorithm.
Main Methods:
- Literature review of current evidence on lipid management in ACS.
- Analysis of patient subgroups for early therapeutic escalation.
- Discussion of novel pharmacological agents in clinical trials.
Main Results:
- Current lipid management often falls short of guideline targets.
- Early identification and intensified therapy can improve outcomes.
- Novel therapies show promise for further LDL-C reduction.
Conclusions:
- Evidence-based lipid management is paramount for improving outcomes in ACS survivors.
- A proactive, algorithm-driven approach to lipid management is needed.
- Novel therapies may offer additional benefits in secondary cardiovascular prevention.
Abstract:
Despite many improvements in its prevention and management, acute coronary syndrome (ACS) remains a major cause of morbidity and mortality in the developed world. Lipid management is an important part of secondary prevention after ACS, but many patients currently remain undertreated and do not attain guideline-recommended levels of low-density lipoprotein cholesterol reduction. This review details the current state of evidence on lipid management in patients presenting with ACS, provides directions for identification of patients who may benefit from early escalation of lipid-lowering therapy, and discusses novel lipid-lowering medication that is currently under investigation in clinical trials. Moreover, a treatment algorithm aimed at attaining guideline-recommended low-density lipoprotein cholesterol levels is proposed. Despite important advances in the initial treatment and secondary prevention of ACS, ≈20% of ACS survivors experience a subsequent ischemic cardiovascular event within 24 months, and 5-year mortality ranges from 19% to 22%. Knowledge of the current state of evidence-based lipid management after ACS is of paramount importance to improve outcomes after ACS.
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Angina IV: Management
Atherosclerosis III: Management
Acute Coronary Syndrome V: Nursing Management
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Acute Coronary Syndrome III: Diagnostic Studies


